CARTITUDE-4 Trial

[Slide 1] Long-Term CARTITUDE-4 Update (34 Months): Safety Profile Consistent With Previous Analysis Cilta-cel SOC Cilta-cel SOC infections SPM (n=208) (n=208) (n=208) (n=208) Treatment-emergent infections. % SPMs.n(%) 27 (13.0) 24 (11.5) All grade 63.5 76.4 Hematologic 7 (3.4) 1(0.5) Grade 3/4 28.4 29.8 MDS. in 4 0 Deaths due to TE- and non-TE infections in 16 19 Progressed to AML n 2 - In first year. n 13 8 AML n 1 0 In second year, n 2 8 Peripheral T-cell lymphoma n 2 0 EBV-associated lymphoma n 0 1 Cilta-cell SOC Cutaneous/non-invasive* 15(7.2) 15(7.2) Cause of death (n=208) (n=208) Non-cutaneous/invasive 6(2.9) 8 (3.8) Deaths, n 50 82 No new cases of cranial nerve palsy or MNT for the Due to progressive disease 21 51 cilta-cell arm since the previous report Due to TEAE 12 8 Both arms had grade 3/4 TEAE around 97% most frequently cytopenia 15

[Slide 1] Parkinsonism: Neurologic toxicity with parkinsonism has been reported in clinical trials of CARVYKTI. Among patients receiving CARVYKTI® in the CARTITUDE-1 & 4 studies, parkinsonism occurred in 3% (8/285), including Grade ≥ 3 in 2% (5/285) of the patients. Median time to onset of parkinsonism was 56 days (range: 14 to 914 days). Parkinsonism resolved in 1 of 8 (13%) of patients with a median time to resolution of 523 days. Median duration of parkinsonism was 243.5 days (range: 62 to 720 days) in all patients including those with ongoing neurologic events at the time of death or data cut off. The onset of parkinsonism occurred after CRS for all patients and after ICANS for 6 patients.

[Slide 1] CAR T Should be Positioned Before BsAbs 1 Treatment-Free Interval & Immune 2 Resistance Patterns Favor CAR T First Recovery BsAbs drive more resistance (43% vs 6% CAR T provides treatment-free interval allowing TNFRSF17 mutations) immune recovery and improved QoL Continuous BsAb exposure increases No increased T-cell exhaustion markers post-CAR T selection of mutations causing resistance 3 Superior Clinical Outcomes 4 Manufacturing Considerations CAR T efficacy diminished after BsAb exposure BsAb before apheresis may compromise CAR T BsAbs maintain efficacy post-CAR T (esp with production target switching BCMA-GPRC5D) Sequential BsAbs yield poor outcomes (T-cell exhaustion)

[Slide 1] Figure 10: Overall Survival, Prior 2 or 3 Lines of Therapy Vs. Prior 1 Line of Therapy Prior 2 or 3 Lines of Therapy Prior 1 Line of Therapy cilta-cel standard therapy cilta-cel standard therapy 1.00 1.00 0.75 0.75 OS Probability 0.50 os Probability 0.50 0.25 0.25 0.00 0.00 0 3 6 9 12 15 18 21 24 27 30 0 3 6 9 12 15 18 21 24 Time from rand omization (months) Time from randomization (months) Number at risk Number at risk cilta-oel 140 135 130 125 115 75 33 17 10 1 0 cilta-cel 68 66 60 58 53 33 20 10 1 $ tandard therapy 143 140 131 122 107 64 26 12 4 0 0 standard therapy 68 67 65 62 58 34 20 9 0 Source: FDA analysis

[Slide 1] Overall Survival With Ciltacabtagene Autoleucel Versus Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Study Update Maria-Victoria Mateos1, Jesús San-Miguel², Binod Dhakal³, Cyrille Touzeau⁴, Xavier Leleu⁵, https: www. congresshub com/Oncology/ MS2024K cel/Mateos Cita Niels WCJ van de Donk⁶, Surbhi Sidana⁷, Albert Oriol8, Yaël C Cohen⁹, Simon J Harrison 11, 12, The QR code is intended to provide scientific Hermann Einsele¹³, Paolo Corradini14, Diana Chen15, Quanlin Li16, Katherine Li17, Ana Slaughter¹⁸, information for individual reference, and the information should not be allered or reproduced Carolina Lonardi19, Nina Benachour20, Martin Vogel²¹, Nikoletta Lendvai²², Mythili Koneru²³, in any way. Nitin Patel²³, Erika Florendo²³, P Joy Ho24, Rakesh Popat25 University Hospital of Salamanca/IBSAL/CIC/CIBERONC Salamanca, Spain; Cancer Center Clinica Universidad Navarra, CIMA, IDISNA, Pamplona, Spain; Medical College of Wisconsin, Milwaukee, WE USA Centre Hospitaler Universitaire de Nantes, Nantes, France; CHU Poitiers, Poitiers, France; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, Stanford University School of Medicine, Stanford, CA, USA; institut Catala d'Oncologia and Institut Josep Carreras, Hospital Germans Trias Pujol, Badalona, Barcelona, Spain Tel Aviv Sourasky (Ichilov) Medical Center, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Peter MacCallum Cancer Centre, Melbourne and Royal Melbourne Hospital, Melbourne, Australia; "Translation Laboratory, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; Universitatskinkum Würzburg, Medizinische Klink und Poliklinik II, Würzburg, Germany, Fondazione RCCS Istituto Nazionale dei Tumori Milano, University of Milano, Italy, Janssen Research & Development, Shanghai, China; "Janssen Research & Development, Apex, NC, USA; 17Janssen Research & Development, Spring House, PA, USA; Cilag GmbH International, Zug, Switzerland, Janssen, Buenos Aires, Argentina, "Janssen Research & Development, Beerse, Belgium; Uanssen Research & Development, Neuss, Germany, 22Janssen Research & Development, Rantan, NJ, USA; 22Legend Biotech USA Inc. Somerset, NJ, USA 2*Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia; University College London Hospitals, NHS Foundation Trust, London, UK esented by M-V Mateos at the 21st International Myeloma Society (IMS) Annual Meeting: September 25-28, 2024; Rio de Janeiro, Brazil ENRIQUE OCIO TANYA WILDES International Myoloma --- [Slide 2] Long-Term CARTITUDE-4 Update (34 Months): Cilta-cel Significantly Improved Overall Survival Median follow-up 33.6 months 100-000 30-month OS 76.4% 80 Cilta-cel 60 % alive 63.8% SOC 40 20 HR (95% CI): 0.55 (0.39-0.79); P=0.0009a,b 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 No. at risk Months Cilta-cel 208 201 190 183 175 173 171 167 163 159 146 93 44 24 9 0 SOC 211 207 196 184 173 163 154 147 137 133 127 71 35 13 4 0 First CAR-T to demonstrate overall survival benefit in multiple myeloma k as test. the P-value, sole explanatory 0.0009, crossed variable. the prespecified boundary of 0.0108 as implemented by the Kim-DeMets spending function with parameter=2. Hazard ratio and 95% CI from a Cox proportional hazards model with meric antigen receptor, cilta-cel, cillacabtagene autoleucel, HR, hazard ratio, OS, overall survival; SOC, standard of care. Presented by M-V Mateos at the 21st International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio de Janeiro, Brazil 7 --- [Slide 3] Long-Term CARTITUDE-4 Update (34 Months): Cilta-cel Maintained Significant Improvement in Progression-Free Survival 100 Median follow-up 33.6 months 30-month PFS 80 % surviving without progression 60 Cilta-cel 59.4% 40 20 00 25.7% " O SOC HR (95% CI): 0.29 (0.22-0.39); P<0.0001ᵃ-ᶜ 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 No. at risk months Cilta-cel 208 177 172 165 157 150 145 136 132 129 111 65 29 13 5 0 SOC 211 176 133 116 96 80 74 65 61 52 47 25 12 1 1 0 ~70% reduction in the risk of progression or death in patients who received cilta-cel and mPFS has not been reached I Pvalue. piecewise weighted log-rank test. HR and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable, including only PFS events that occurred >8 weeks post randomization. littacabtagene autoleucel, HR, hazard ratio; mPFS, median progression-free survival, PFS, progression-free survival; SOC, standard of care. Presented by M-V Mateos at the 21st International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024; Rio de Janeiro, Brazil 9 --- [Slide 4] Long-Term CARTITUDE-4 Update (34 Months): Cilta-cel Significantly Extended Time to Symptom Worsening Time to symptom worsening (MySIm-Q total symptom scale)ᵃ 100 80 0 SOC % worsening 60 & 40 00 10:00 e w 0.00 Cilta-cel 20 HR (95% CI): 0.38 (0.24-0.61); P<0.0001b,c 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 months No. at risk Cilta-cel 208 169 159 150 134 126 116 114 90 87 41 37 8 2 0 SOC 211 128 103 87 65 62 54 49 44 41 17 11 1 0 0 Cilta-cel improved QoL vs SOC by extending time to symptom worsening Median follow-up, 33.6 months Log-rank test HR and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable Cita cel, citacabtagene autoleucel; HR, hazard ratio; MySim-Q Multiple Myeloma Symptom and Impact Questionnaire; QoL, quality of de: SOC, standard of care. 14 Presented by M.V Mateos at the 21st International Myeloma Society (IMS) Annual Meeting: September 25-28, 2024; Rio de Janeiro, Brazil ENRIQUE OCIO TANYA WILDES International

[Slide 1] NOT 2 of the same kind CARTITUDE-4 KARMMA-3 LOT eligibility 1-3 2-4 Exposure eligibility IMiD and PI IMiD, PI, anti-CD38 Refractoriness eligibility Lenalidomide Last line Age 61.5 63 Median prior LOT 2 3 Refractory to anti-CD38 24% 95% Refractory to IMiD 100% 88% Triple-class refractory 14% 65% t(4;14), t(14;16) or del (17p) 35% 42% Extra-medullary plasmacytoma 21% 24% Carfilzomib allowed control arm No Yes CAR-T on control arm after PD No Yes ORR of control arm 67% 42% mPFS of control arm (mo.) 11.8 4.4 HR for PFS 0.26 (0.18-0.38) 0.49 (0.38-0.65)